Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PALB2 Antibodies:
anti-Mouse (Murine) PALB2 Antibodies:
anti-Rat (Rattus) PALB2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal PALB2 Primary Antibody for ICC, IF - ABIN253057
Brough, Bajrami, Vatcheva, Natrajan, Reis-Filho, Lord, Ashworth: APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. in The EMBO journal 2012
Show all 2 Pubmed References
Human Polyclonal PALB2 Primary Antibody for IHC, IP - ABIN253058
Martrat, Maxwell, Tominaga, Porta-de-la-Riva, Bonifaci, Gómez-Baldó, Bogliolo, Lázaro, Blanco, Brunet, Aguilar, Fernández-Rodríguez, Seal, Renwick, Rahman, Kühl, Neveling, Schindler, Ramírez et al.: Exploring the link between MORF4L1 and risk of breast cancer. ... in Breast cancer research : BCR 2011
Human Polyclonal PALB2 Primary Antibody for EIA, WB - ABIN5555098
Loke, Pearlman, Upadhyay, Tesfa, Shao, Ostrer: Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway. in Human molecular genetics 2016
Study found a frameshift mutation which segregates in an early onset HBOC family; and four rare missense variants. None of the variants tested for a predicted splicing disruption showed an aberrant transcript pattern. Although PALB2 truncating mutations are rarely identified, segregation analysis and early onset cancer suggest a significant contribution to HBOC susceptibility in the Spanish population.
Study shows that BRCA1, PALB2 and BRCA2 can all play a significant role in both checkpoint activation and checkpoint maintenance, depending on cell type and context, and that PALB2 links BRCA1 and BRCA2 in the checkpoint response. The BRCA1-PALB2 interaction can be important for checkpoint activation, whereas PALB2-BRCA2 complex appears to be more critical for checkpoint maintenance.
Our results validate the integration of PALB2, RAD51C, and RAD51D in the diagnosis of hereditary breast and ovarian cancer and suggest that the other genes are involved in an oligogenic determinism.
Our findings indicate that in the Indian population, there is a high prevalence of mutations in the high-risk breast cancer genes: BRCA1, BRCA2, TP53, and PALB2.
We identified a cluster of interacting genes involved in DNA repair that could be associated with predisposition to hereditary diffuse gastric cancer, in particular, PALB2.
The associations between five SNPs of PALB2 and breast cancer risk.
Our data presented the germline mutation status of PALB2 in Chinese breast cancer patients, suggesting that loss-of-function germline mutations of PALB2 are important in both familial and sporadic breast cancer. Clinically, these data may be helpful in genetic counseling of breast cancer patients with PALB2 germline mutation.
Truncating variants in PALB2, ATM and CHEK2 , but not XRCC2 were associated with increased breast cancer risk.
PALB2 associates with active genes through its major binding partner, MRG15, which recognizes histone H3 trimethylated at lysine 36 (H3K36me3) by the SETD2 methyltransferase
the involvement of PALB2 mutations in the predisposition to cancer and the role of PALB2 in stimulating error-free DNA repair through the FA/HR pathway.
FANCD2 and PALB2, as indicators of the upstream and downstream arms, respectively, colocalize independently of each other in response to DNA damage.
The findings demonstrate that RNF168 couples PALB2-dependent homologous recombination to H2A ubiquitylation to promote DNA repair and preserve genome integrity.
The results of the present study suggest that mutations in the PALB2 gene may be particularly relevant to breast cancer susceptibility in the Jamaican population.
We identified two PALB2 mutations that are founder alleles in Italian families, one of which is, independently, also a founder mutation in American-Hispanic breast cancers.
Our results indicate that the PALB2 exon 13 duplication is a pathogenic variant. The presence of the PALB2 duplication in the proband affected with high-grade serous ovarian cancer suggests that PALB2 might be associated with a predisposition to ovarian cancer.
We showed that the mutation frequency of RAD51C in Japanese familial breast cancer cases was similar to that in Western countries and that the prevalence of deleterious mutation of PALB2 was possibly lower. Furthermore, our results suggested that BRIP1 mutation frequency in Japan might differ from that in Western countries
Study have shown that mutations in BRCA1, BRCA2, and PALB2 account for more than 10 % of breast cancer in Trinidad and Tobago. 25 different mutations identified; of these, four mutations were seen in two patients each.
Germline mutations in the PALB2 gene were observed at a frequency of approximately 1.5% in Polish breast and/or ovarian cancer patients
Prevalence of germline PALB2 mutations among women with epithelial ovarian cancer in Ontario
inherited pathogenic variants in PALB2 were associated with high risks of breast cancer
we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 and Trp53 heterozygosity .
results underscore the in vivo importance of the PALB2-BRCA1 complex formation in DSB repair and male meiosis
Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
A key function for PALB2 is to interact with and to build up appropriate communication between BRCA1 and BRCA2.
This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2.
partner and localizer of BRCA2
, Fanconi N
, Fanconi anemia
, complementation group N
, partner and localizer of BRCA2-like